Drug Trial Radar · NCT07298772
A Study of SHR-4375 Injection in Combination With Other Antitumor Therapies in Patients With Solid Tumors
Last checked: Nov 19, 2026Latest source record: May 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
198
Planned (sponsor's estimate)
Start
Jan 7, 2026
Primary completion
Jan 2027
Study completion Jan 2028
Sponsor
- Lead sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 23, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open label, multi-center, Phase Ib/II study to evaluate the safety, tolerability and efficacy of SHR-4375 injection in combination with other antitumor therapies in patients with advanced solid tumors.
Conditions
- Advanced Solid Tumor
Interventions
SHR-4375 InjectionDrug
SHR-4375 injection in combination with other antitumor therapies.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose limiting toxicity (DLT).Time frame: 3 weeks.
- Recommended phase II dose (RP2D).Time frame: From screening period up to study completion, an average of 1 year.
- Adverse events (AEs).Time frame: From screening period up to study completion, an average of 1 year.
- Objective response rate (ORR).Time frame: From screening period up to study completion, an average of 1 year.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.